To add to the thoughts about Parkinson's and mitochondria, here is a study showing that oxidative stress is tied to it.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135313/
The Role of Oxidative Stress in Parkinson’s Disease
Vera Dias,
Eunsung Junn, and
M. Maral Mouradian*
Along with that, and tied to that, there is iron deposition.
http://www.sciencedirect.com/science/article/pii/S0925443911001426
Neurodegeneration with brain iron accumulation — Clinical syndromes and neuroimaging
Interesting - Shungu's studies certainly indicate a high likelihood of oxidative stress in ME/CFS patients brains
Oxidative stress plays an important role in the degeneration of dopaminergic neurons in Parkinson’s disease (PD). Disruptions in the physiologic maintenance of the redox potential in neurons interfere with several biological processes, ultimately leading to cell death. Evidence has been developed for oxidative and nitrative damage to key cellular components in the PD substantia nigra. A number of sources and mechanisms for the generation of reactive oxygen species (ROS) are recognized including the metabolism of dopamine itself, mitochondrial dysfunction, iron, neuroinflammatory cells......
The brain consumes about 20% of the oxygen supply of the body, and a significant portion of that oxygen is converted to ROS [
43]. ROS can be generated in the brain from several sources, both in neurons and glia, with the electron transport chain being the major contributor at the mitochondrial level [
44,
45].....
Dopamine agonists have been suggested to have neuroprotective and antioxidant effects [
406]. For example, pramipexole protects MES 23.5 cells against hydrogen peroxide, dopamine and L-dopa induced toxicity [
407]. It also reduces lipid peroxidation and minimizes injury to the SN of MPTP lesioned mice [
408]. The antioxidant effect of pramipexole independent of its dopamine receptor agonist property can be responsible for its neuroprotective action [
409]. It can reduce the levels of oxygen radicals produced by MPP+ both when incubated with SH-SY5Y cells and when perfused into the rat striatum [
410]. Similarly, ropinirole protects mice against 6-OHDA by increasing glutathione levels [
411,
412]........
Among agents that might alleviate oxidative stress, creatine is an antioxidant involved in the inhibition of the opening of the mitochondrial permeability pore and affects mitochondrial energy production [
437–
439]. In mice, creatine has been shown to protect against MPTP-induced dopaminergic depletion in the SN [
440]. Two phase II studies of creatine in PD patients have yielded contradictory results, one failing to show efficacy [
441] while the other reporting about 40% less worsening of motor Unified PD Rating Scale scores at one year [
442]. In a follow up phase II NET-PD futility study, creatine use at 18 months did not show safety concerns, but the phase III trial was recently terminated due to lack of statistically significant difference from placebo [
443,
444].
Other attempts to use compounds with antioxidant properties in PD have included tocopherol (vitamin E), vitamin C, Coenzyme Q10, docosahexaenoic acid (DHA), Ginkgo biloba, or polyphenols found in green tea [
431,
445–
451]. None of these have yielded convincing evidence for neuroprotective efficacy....
Recently,
ketogenic diet has been suggested as a potential therapy in neurological diseases, since the mitochondrial Complex II activator D-beta-hydroxybutyrate, a ketone body, has been shown to increase cellular GSH content, decrease intracellular ROS production induced by H2O2, inhibit apoptosis and enhance cell viability [
452]. Although this diet has not been studied in animal models of PD yet, a caloric restriction diet conferred resistance to MPTP in mice, rats and rhesus monkeys [
453–
455]. Interestingly, an uncontrolled study of five patients with PD placed on a ketogenic diet for 28 days reported a 43% improvement in their Unified PD Rating Scale scores [
456].